Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07003542 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Jun 24, 2026, no change to tracked fieldsv7-v8
  2. Start date: Aug 8, 2025 to Mar 16, 2026v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2025 to Aug 8, 2025
    • Site details revised
    v5
  4. Start date: Jun 2025 to Sep 2025v4
  5. Re-verified, no change to tracked fieldsv3
  6. Secondary endpoints: details revised at 1 of 4 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate whether treating glioblastoma patients with sitagliptin can improve immune response against the tumor by targeting specific immune cells called myeloid-derived suppressor cells (MDSCs) that suppress your body's natural immune response against cancer. Sitagliptin is an investigational drug for this condition that works by inhibiting an enzyme called dipeptidyl peptidase 4 (DPP-4), which MDSCs rely on to enter the brain and function. While sitagliptin is FDA-approved for diabetes treatment, its use in glioblastoma is investigational (experimental).
Trial Details
NCT Number NCT07003542
Lead Sponsor Case Comprehensive Cancer Center
Conditions
(from sponsor)		 Glioblastoma, Brain Tumor
Related terms Brain Neoplasms, Glioblastoma
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov